SAN CARLOS, CA — Sift Biosciences is proud to announce that Dr. Yue Clare Lou, Co-Founder and CEO of Sift Biosciences, has been named to the Forbes 30 Under 30 list in Healthcare this year, recognizing her work in advancing next-generation immunotherapies for cancer and autoimmune disease.
About Sift Biosciences
Sift Biosciences is a preclinical immunotherapy company developing immunomodulators that harness pre-existing memory T-cells to treat immune dysfunctions. Founded in 2024 as a UC Berkeley spin-out, Sift integrates AI and high-throughput T-cell screening to mine billions of microbial proteins for motifs that activate antimicrobial memory T-cells and steer them toward tumor antigens, autoantigens, and other disease-relevant targets. The company’s initial focus is on oncology, with expanding pipelines in autoimmunity and immunosenescence.